Johnson & Johnson bought the full rights to a rare disease gene therapy a few years ago, but now the Big Pharma may be ...

McEvoy is a President, Chief Executive Officer & Director at Insulet Corp., an Independent Director at Procter & Gamble Co., an Assistant Manager-Brand at McNeil Consumer Healthcare and a Chairman & ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Alex Hacopian, MD, speaks about patient-reported outcomes from a presbyopia-correcting IOL at the 2025 ASCRS annual meeting.

Patients implanted with a presbyopia-correcting IOL reported high satisfaction after surgery and preserved visual acuity in ...

Insulet announced today that its board of directors appointed Ashley McEvoy as president and CEO, effective immediately.

Excellent visual outcomes at distance, intermediate, and near, Minimal issues with dysphotopsias, and High spectacle independence. Real-World Evidence Visual Outcomes of a Full Visual Range ...

Its MedTech segment offers medical devices across orthopaedics, surgery, and vision care. JNJ ranked eighth on our recent list of 10 Best Low Risk Stocks To Buy in 2025. Johnson & Johnson (NYSE ...

Beth Marsh will lead commercialization for Neurotech, which gained FDA approval for its eye disease therapy. Neurotech in May ...

The global cataract surgery device market is poised for significant growth, projected to expand from USD 8,928 million in 2024 to an estimated USD 12,472.70 million by 2034. This robust increase, ...